Free Trial

AbbVie (ABBV) 10K Form and Latest SEC Filings 2026

AbbVie logo
$210.54 -0.23 (-0.11%)
Closing price 05/15/2026 03:59 PM Eastern
Extended Trading
$210.80 +0.26 (+0.12%)
As of 05/15/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest AbbVie SEC Filings & Recent Activity

AbbVie (NYSE:ABBV) has submitted 622+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in AbbVie's financial statements. The most recent filing was a Form 8-K submitted on May 12, 2026.

Form 4
AbbVie Inc. Reports Ownership Change on May. 12, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
AbbVie Files Current Report on May. 12, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
AbbVie Files Quarterly Report on May. 8, 2026

The 10-Q contains AbbVie's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

AbbVie SEC Filing History

Browse AbbVie's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
AUSTIN ROXANNE S (1061632) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
BURNSIDE WILLIAM H.L. (1563579) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
Davis Jennifer L. (1916665) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
FREYMAN THOMAS C (1239126) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
Hart Brett J (1466338) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
MEYER MELODY B (1706126) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
Quaggin Susan E (1997505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
RAPP EDWARD J (1171780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
Roberts Rebecca B (1355580) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
WADDELL FREDERICK H (1223690) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:00 PM
AbbVie (1551152) Issuer
FALK THOMAS J (1222890) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:01 PM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2026 11:28 AM
AbbVie (1551152) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2026 6:50 AM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/03/2026 3:05 PM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/02/2026 4:00 PM
AbbVie (1551152) Issuer
Alpern Robert J (1448074) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 4:00 PM
AbbVie (1551152) Issuer
RAPP EDWARD J (1171780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 4:00 PM
AbbVie (1551152) Issuer
Quaggin Susan E (1997505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 2:06 PM
AbbVie (1551152) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/23/2026 3:59 PM
AbbVie (1551152) Filer
Form DEF 14A
03/23/2026 4:01 PM
AbbVie (1551152) Filer
Form DEFA14A
03/23/2026 4:09 PM
AbbVie (1551152) Filer
Form ARS
03/11/2026 4:00 PM
AbbVie (1551152) Issuer
Purdue David Ryan (2057696) Reporting
Form 4/A
03/03/2026 5:10 PM
AbbVie (1551152) Issuer
Donoghoe Nicholas (1762951) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:10 PM
AbbVie (1551152) Issuer
SALEKI-GERHARDT AZITA (1563545) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:10 PM
AbbVie (1551152) Issuer
Purdue David Ryan (2057696) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:10 PM
AbbVie (1551152) Issuer
Reents Scott T (1937048) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:10 PM
AbbVie (1551152) Issuer
Siatis Perry C (1951400) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:10 PM
AbbVie (1551152) Issuer
Stewart Jeffrey Ryan (1761675) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:12 PM
AbbVie (1551152) Issuer
Michael Robert A. (1699914) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 5:14 PM
AbbVie (1551152) Issuer
Thakkar Roopal (2004979) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 4:14 PM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2026 3:36 PM
AbbVie (1551152) Subject
Form FWP
02/25/2026 3:49 PM
AbbVie (1551152) Subject
Siatis Perry C (1951400) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/24/2026 7:18 AM
AbbVie (1551152) Filer
Form 424B5
02/20/2026 5:35 PM
AbbVie (1551152) Issuer
Michael Robert A. (1699914) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 5:35 PM
AbbVie (1551152) Issuer
Reents Scott T (1937048) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 5:35 PM
AbbVie (1551152) Issuer
Donoghoe Nicholas (1762951) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 5:35 PM
AbbVie (1551152) Issuer
Crum Demetris D (2078592) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 5:35 PM
AbbVie (1551152) Issuer
SALEKI-GERHARDT AZITA (1563545) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 5:35 PM
AbbVie (1551152) Issuer
Siatis Perry C (1951400) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad)

Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel

Get the name and ticker of Louis Navellier's #1 AI stock free
02/20/2026 5:35 PM
AbbVie (1551152) Issuer
Stewart Jeffrey Ryan (1761675) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 5:35 PM
AbbVie (1551152) Issuer
Purdue David Ryan (2057696) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 5:36 PM
AbbVie (1551152) Issuer
Thakkar Roopal (2004979) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 1:38 PM
AbbVie (1551152) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/04/2026 6:54 AM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 3:08 PM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2026 4:00 PM
AbbVie (1551152) Issuer
RAPP EDWARD J (1171780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 4:00 PM
AbbVie (1551152) Issuer
Quaggin Susan E (1997505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 4:00 PM
AbbVie (1551152) Issuer
Alpern Robert J (1448074) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2025 1:05 PM
AbbVie (1551152) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/31/2025 6:51 AM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2025 3:09 PM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2025 6:30 AM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/22/2025 5:02 PM
AbbVie (1551152) Subject
GONZALEZ RICHARD A (1239127) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/21/2025 5:04 PM
AbbVie (1551152) Subject
GONZALEZ RICHARD A (1239127) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/12/2025 6:22 PM
AbbVie (1551152) Subject
SALEKI-GERHARDT AZITA (1563545) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/08/2025 4:03 PM
AbbVie (1551152) Subject
GONZALEZ RICHARD A (1239127) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/05/2025 3:40 PM
AbbVie (1551152) Subject
Donoghoe Nicholas (1762951) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/04/2025 2:17 PM
AbbVie (1551152) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/31/2025 6:48 AM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/30/2025 4:00 PM
AbbVie (1551152) Issuer
Crum Demetris D (2078592) Reporting
Form 3/A
07/11/2025 5:20 PM
AbbVie (1551152) Reporting
Form 3
Initial statement of beneficial ownership of securities  
07/07/2025 12:20 PM
AbbVie (1551152) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
07/03/2025 12:07 PM
AbbVie (1551152) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

AbbVie SEC Filings - Frequently Asked Questions

AbbVie (ABBV) has submitted 622+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

AbbVie's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on AbbVie's financial statements page.

The most recent filing was a Form 8-K submitted on May 12, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSE:ABBV) was last updated on 5/17/2026 by MarketBeat.com Staff.
From Our Partners